SCHEMBL20142566

SCHEMBL20142566

CN(C)CCCNC(=O)C1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.50
PTPN2 P17706 1/20 0.50
PTPN1 P18031 1/20 0.50
PTPN6 P29350 1/20 0.50
RECQL P46063 1/20 0.48
LMNA P02545 1/20 0.47
HSD17B10 Q99714 1/20 0.47
KEAP1 Q14145 1/20 0.47
NFE2L2 Q16236 1/20 0.47
STS P08842 3/20 0.46
KMT2A Q03164 3/20 0.46
HDAC8 Q9BY41 1/20 0.46
EPHX2 P34913 1/20 0.46
KDM1A O60341 1/20 0.46
EHMT2 Q96KQ7 1/20 0.46
RCOR1 Q9UKL0 1/20 0.46
EPHX1 P07099 1/20 0.45
MEN1 O00255 2/20 0.45
ALDH1A1 P00352 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1245504 0.92 HPGD (0.52) HPGDPTPN2PTPN1PTPN6RECQL
SCHEMBL19840511 0.88 HPGD (0.51) HPGDPTPN2PTPN1PTPN6RECQL
SCHEMBL19840507 0.87 TDP1 (0.52) HPGDPTPN2PTPN1PTPN6RECQL
SCHEMBL1440590 0.86 GAA (0.53) HPGDPTPN2PTPN1PTPN6RECQL
SCHEMBL23466442 0.86 HPGD (0.55) HPGDPTPN2PTPN1PTPN6RECQL
SCHEMBL20542744 0.84 NAAA (0.57) HPGDPTPN2PTPN1PTPN6RECQL
SCHEMBL19840496 0.84 HDAC8 (0.51) HPGDPTPN2PTPN1PTPN6RECQL
SCHEMBL19840500 0.83 HDAC8 (0.52) HPGDPTPN2PTPN1PTPN6RECQL
SCHEMBL2262424 0.82 HPGD (0.54) HPGDPTPN2PTPN1PTPN6RECQL
SCHEMBL21569666 0.82 LMNA (0.50) HPGDLMNAHSD17B10KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12378255-B2 Toll-like receptor antagonist compounds and methods of use DYNAVAX TECHNOLOGIES CORPORATION (US) 2025-08-05 US disclosed
US-20240182478-A1 TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE DYNAVAX TECHNOLOGIES CORPORATION 2024-06-06 US disclosed
US-11827641-B2 Toll-like receptor antagonist compounds and methods of use DYNAVAX TECHNOLOGIES CORPORATION (US) 2023-11-28 US disclosed
US-11827641-B2 Toll-like receptor antagonist compounds and methods of use DYNAVAX TECHNOLOGIES CORPORATION (US) 2023-11-28 US disclosed
US-20220298162-A1 TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE DYNAVAX TECHNOLOGIES CORPORATION (US) 2022-09-22 US disclosed
US-11370794-B2 Toll-like receptor antagonist compounds and methods of use DYNAVAX TECHNOLOGIES CORPORATION (US) 2022-06-28 US disclosed
US-11370794-B2 Toll-like receptor antagonist compounds and methods of use DYNAVAX TECHNOLOGIES CORPORATION (US) 2022-06-28 US disclosed
US-20190345161-A1 TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE DYNAVAX TECHNOLOGIES CORPORATION (US) 2019-11-14 US disclosed
US-20190345161-A1 TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE DYNAVAX TECHNOLOGIES CORPORATION (US) 2019-11-14 US disclosed
EP-3538513-A1 TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE Dynavax Technologies Corporation (US) 2019-09-18 EP disclosed
WO-2018089695-A1 TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE DYNAVAX TECHNOLOGIES CORPORATION (US) 2018-05-17 WO disclosed
WO-2018089695-A1 TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE DYNAVAX TECHNOLOGIES CORPORATION (US) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220298162-A1 TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE TLR7, TLR9, TLR1 HPGD 3552/4885PTPN2 237/4885PTPN1 216/4885
US-20240182478-A1 TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE TLR7, TLR9, TLR1 HPGD 3552/4885PTPN2 237/4885PTPN1 216/4885
US-11827641-B2 Toll-like receptor antagonist compounds and methods of use TLR7, TLR9, TLR1 HPGD 3552/4885PTPN2 237/4885PTPN1 216/4885
US-20190345161-A1 TOLL-LIKE RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USE TLR7, TLR9, TLR1 HPGD 3552/4885PTPN2 237/4885PTPN1 216/4885
US-11370794-B2 Toll-like receptor antagonist compounds and methods of use TLR9, TLR7, TLR8 HPGD 3971/4885PTPN2 205/4885PTPN1 190/4885
US-12378255-B2 Toll-like receptor antagonist compounds and methods of use TLR7, TLR9, TLR1 HPGD 3552/4885PTPN2 237/4885PTPN1 216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.